206 related articles for article (PubMed ID: 16342952)
1. Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.
Wiseman RL; Powers ET; Kelly JW
Biochemistry; 2005 Dec; 44(50):16612-23. PubMed ID: 16342952
[TBL] [Abstract][Full Text] [Related]
2. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
3. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.
Quintas A; Vaz DC; Cardoso I; Saraiva MJ; Brito RM
J Biol Chem; 2001 Jul; 276(29):27207-13. PubMed ID: 11306576
[TBL] [Abstract][Full Text] [Related]
4. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.
Yang M; Yordanov B; Levy Y; Brüschweiler R; Huo S
Biochemistry; 2006 Oct; 45(39):11992-2002. PubMed ID: 17002298
[TBL] [Abstract][Full Text] [Related]
5. Initial conformational changes of human transthyretin under partially denaturing conditions.
Yang M; Lei M; Bruschweiler R; Huo S
Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
[TBL] [Abstract][Full Text] [Related]
6. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
Lai Z; McCulloch J; Lashuel HA; Kelly JW
Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
8. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
Wiseman RL; Green NS; Kelly JW
Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the Misfolding Mechanism of Transthyretin Monomer: Insights from Hybrid-Resolution Simulations and Markov State Model Analysis.
Zhou S; Cheng J; Yang T; Ma M; Zhang W; Yuan S; Lo GV; Dou Y
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31861226
[TBL] [Abstract][Full Text] [Related]
10. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
Hurshman AR; White JT; Powers ET; Kelly JW
Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
[TBL] [Abstract][Full Text] [Related]
12. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
Hammarström P; Jiang X; Deechongkit S; Kelly JW
Biochemistry; 2001 Sep; 40(38):11453-9. PubMed ID: 11560493
[TBL] [Abstract][Full Text] [Related]
13. A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.
Jesus CS; Almeida ZL; Vaz DC; Faria TQ; Brito RM
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589730
[TBL] [Abstract][Full Text] [Related]
14. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
15. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
17. Two distinct aggregation pathways in transthyretin misfolding and amyloid formation.
Dasari AKR; Hung I; Gan Z; Lim KH
Biochim Biophys Acta Proteins Proteom; 2019 Mar; 1867(3):344-349. PubMed ID: 30366153
[TBL] [Abstract][Full Text] [Related]
18. A transthyretin monomer intermediate undergoes local unfolding and transient interaction with oligomers in a kinetically concerted aggregation pathway.
Sun X; Ferguson JA; Dyson HJ; Wright PE
J Biol Chem; 2022 Aug; 298(8):102162. PubMed ID: 35724960
[TBL] [Abstract][Full Text] [Related]
19. Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.
Ferreira P; Sant'Anna R; Varejão N; Lima C; Novis S; Barbosa RV; Caldeira CM; Rumjanek FD; Ventura S; Cruz MW; Foguel D
PLoS One; 2013; 8(12):e82484. PubMed ID: 24358189
[TBL] [Abstract][Full Text] [Related]
20. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
